Recommendations for Liquid Chromatography-Mass Spectrometry in the Clinical Laboratory: Part III. Quality Assurance
10.3343/lmo.2020.10.3.185
- Author:
Serim KIM
1
,
2
;
Sang-Guk LEE
;
Soo Young MOON
;
Hyung-Doo PARK
;
Sang Hoon SONG
;
Kyunghoon LEE
;
Hyun-Jung CHOI
;
Soo-Youn LEE
;
Author Information
1. Department of Laboratory Medicine, Green Cross Laboratories, Yongin
2. , Korea
- Publication Type:Guideline
- From:Laboratory Medicine Online
2020;10(3):185-196
- CountryRepublic of Korea
-
Abstract:
The use of liquid chromatography-tandem mass spectrometry (LC-MS/MS) in clinical laboratories is increasing and is likely to expand into even more clinical venues in the future. Mass spectrometry is the standard method for analyte identification in the clinical chemistry field; however, differences in mass spectrometry protocols and handling affect the accuracy and reliability of these tests and prevent direct comparisons of results between laboratories. For example, the results of laboratories using LC-MS/MS methods are less likely to be reproducible than those of laboratories using conventional, automated methods. This is due to inadequate handling of the equipment and/or poor quality control after the implementation of the method, which may result in unnecessary medical expenditures or even adverse outcomes for the patients. Unfortunately, guidelines to monitor the accuracy of LC-MS/MS-based clinical tests are still lacking. In general, the quality control methods used in conventional clinical tests could also be applied to LC-MS/MS. However, additional quality control methods specific to LC-MS/MS techniques must be continuously employed to maintain the same quality level achieved during method development and verification. This report is intended to help clinical laboratories that operate LC-MS/MS improve the accuracy and reliability of their testing by providing guidance for quality assurance and improvement, based on a collection of existing guidelines and expert opinions from the literature.
